SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating significant social media buzz among retail traders who are attracted to its ultra-low circulating supply and potential for rapid volatility. Community members are actively debating the token's long-term utility versus its speculative appeal, frequently highlighting its scarcity as a primary catalyst for potential price appreciation.

EOG Resources, Inc. engages in the exploration, development, production and marketing of crude oil and natural gas. It operates through the United States, Trinidad, and Other International geographical segments. The Other International segment includes China and Canada operations. The company was founded in 1985 and is headquartered in Houston, TX.

EOG Resources, Inc.

EOG Resources is capturing investor attention following a significant $5.6 billion acquisition of Encino Acquisition Partners in the Utica Shale, a move that aims to bolster production capacity and long-term shareholder value. Community discussions remain focused on the company's operational discipline and dividend reliability as investors weigh its aggressive growth strategy against the backdrop of fluctuating energy commodity prices.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending as investors react to a significant $5.75 billion acquisition of Lumen Technologies' consumer fiber assets and a separate multibillion-dollar spectrum deal with EchoStar. While the market monitors these infrastructure investments and robust capital return plans, the community remains actively divided between those viewing the stock as a long-term undervalued income play and those concerned about the company's significant debt load and ongoing competition.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently a focal point for investors seeking a proxy for the anticipated SpaceX IPO, with the stock gaining significant momentum as shareholders capitalize on the company's strategic spectrum deals that secured a substantial equity stake in the space giant. The community is actively discussing the valuation impact of a potential SpaceX public offering, with many debating the stock's long-term potential as a leveraged play on satellite infrastructure and the broader space economy.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital is seeing intense community debate as investors grapple with the recent 50% dividend cut, which management implemented to prioritize NAV stability and reinvestment in CLO assets. While some shareholders are calling it a capitulation event and expressing deep frustration over the persistent share price decline, others are using the pullback to add to positions, betting that the reduced payout will ultimately stabilize the fund's long-term performance.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending as investors weigh its upcoming FDA Type A meeting to discuss the recent complete response letter for its lead melanoma drug, RP1. While the community remains divided over the likelihood of an accelerated approval pathway, many are closely monitoring the stock for potential rebound opportunities driven by strong clinical data and a significant cash runway.

The White Whale

White Whale Crypto is experiencing intense community debate and trading volume as investors react to significant token burns and long-term supply locks intended to signal project legitimacy. While some participants hail it as a revolutionary movement challenging rigged financial systems, others remain skeptical, warning of potential market manipulation and typical pump-and-dump patterns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The DJT stock is currently at the center of heated online debate as community members clash over the administration's military actions in the Middle East and the resulting impact on the global economy. Investors and critics alike are actively discussing recent reports of downed aircraft, questions regarding the administration's strategic goals, and the potential long-term financial consequences of the ongoing conflict.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

The YETH ETF is currently in the spotlight as investors navigate its transition to a weekly distribution model while balancing potential for consistent income against the underlying volatility of Ethereum. Community members are actively debating the fund's NAV performance and comparing its distribution yields to broader crypto-linked assets, with many split between using it as a tactical income tool or a long-term holding.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00

Roth Mkm decreased their price objective on Cingulate from $16.00 to $14.00 and set a "buy" rating for the company in a research report on Monday...

What's Going On With Cingulate Stock Today?

Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.read more...

Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Cingulate (NASDAQ:CING - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28...

Cingulate (CING) Expected to Announce Earnings on Thursday

Cingulate (NASDAQ:CING) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-cingulate-inc-stock...

<ul class="summary-bullets"><li>The USPTO cleared a patent filed in November 2023, with a status indicating it has been approved and the patent is expected to be issued.</li><li>The filing covers drug-delivery technologies for neurological treatments, including ADHD.</li><li>The technology supports Cingulate’s Precision Timed Release (PTR) platform, used in CTx-1301, an ADHD drug.</li></ul>Shares of Cingulate, Inc. (CING) jumped over 4% in overnight trading on Sunday after the U.S. Patent and Trademark Office (PTO) cleared a key patent application tied to the company’s ADHD drug platform, adding another potential catalyst ahead of a major regulatory decision expected in May.<a href="https://stocktwits.com/symbol/CING">CING stock</a> snapped four straight sessions of gains on Friday to end nearly 5% lower at $8.69.<h2 class="st-heading-2">Patent Office Clears Cingulate ADHD Drug Patent</h2>Patent records show the USPTO has allowed a patent titled “Trimodal, Precision-Timed Pulsatile Release Tablet.” The application, filed in November 2023, is now listed with the status “Allowed - Notice of Allowance Not Yet Mailed” as of Sunday. An allowed status means the patent examiner has approved the claims, and the patent will be issued once final administrative steps are completed.The inventors listed on the filing include Matthew Brams, Cingulate’s chief medical officer, Raul Silva, its chief science officer, and Arthur Straughn, a co-founder of the company. It also names Cingulate as the applicant. The application covers drug-delivery technologies classified for neurological treatments, including attention-deficit/hyperactivity disorder (ADHD).<h2 class="st-heading-2">How Cingulate’s ADHD Drug Technology Works</h2>The patent application centers on a trimodal pulsatile-release tablet that releases medication at multiple timed intervals throughout the day. The tech aligns with Cingulate’s Precision Timed Release (PTR) platform, which the company is using to develop next-generation treatments for ADHD and other neurological conditions.The approach aims to address common challenges with stimulant medications, including midday rebound and the need for multiple doses. CTx-1301 uses dexmethylphenidate, a stimulant already approved to treat ADHD, delivered through Cingulate’s Precision Timed Release platform. It releases dexmethylphenidate in three timed pulses, with the final dose delivered around the time when many extended-release stimulant medications begin to wear off. The company said the design aims to provide rapid symptom relief in the morning and consistent symptom control into the evening.In 2024, the company received a European patent for its CTx-1301, which covers up to 30 European territories, including the UK. The company also holds patents in Australia, Canada, and Israel.<h2 class="st-heading-2">FDA Decision Looms For ADHD Drug</h2>The patent development comes ahead of a key regulatory milestone for Cingulate’s lead program. In October 2025, the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application for CTx-1301 for the treatment of ADHD in children and adults. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of May 31.The application is being reviewed under a regulatory pathway that allows companies to reference existing data for approved ingredients while showing new clinical benefits through different delivery technologies. Cingulate completed Phase 3 trials in adult and pediatric patients before submitting the application. The studies showed improvements in ADHD symptoms and demonstrated sustained efficacy across the day.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CING shifted to ‘extremely bullish’ from the ‘bullish’ zone over the past month amid a 675% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cing_ss_png_1c541a03cd.webp" alt="cing ss.png" width="968" height="141"><figcaption>CING sentiment and message volume as of March 15 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/stockchacing/message/647581086">said</a>, “Can’t wait for Monday, interesting week ahead of us.”<stembedurl>https://stocktwits.com/stockchacing/message/647581086</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/fullobullz/message/647578844">said</a>, “Fuel up the rockets, time to ride to moon.”<stembedurl>https://stocktwits.com/fullobullz/message/647578844</stembedurl>CING stock has doubled so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CING stock has doubled so far this year. (Photo credit: Getty Images)

Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst

The FDA has set May 31 as the PDUFA target date to decide on Cingulate’s ADHD drug CTx-1301.

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Equity

Cingulate (NASDAQ:CING) Trading Up 6.5% - Here's What Happened

Cingulate (NASDAQ:CING) Shares Up 6.5% - Here's Why...

Cingulate (NASDAQ:CING) CEO Shane Schaffer Purchases 6,809 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer acquired 6,809 shares of the company's stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost...

Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CFO Jennifer Callahan purchased 4,864 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer purchased 6,809 shares of Cingulate stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average...

Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) Director Peter Werth acquired 19,455 shares of the company's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CING News

CINGCingulate Inc